This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lamszus, K. Articles by Westphal, M. Search for Related Content PubMed PubMed Citation Articles by Lamszus, K. Articles by Westphal, M.

Levels of Soluble Vascular Endothelial Growth Factor (VEGF) Receptor 1 in Astrocytic Tumors and Its Relation to Malignancy, Vascularity, and VEGF-A¹

Departments of Neuropathology [K. L.] and Neurosurgery [U. U., M. A. B., R. F., M. W.] and Institute of Legal Medicine [J. M.], University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany

Purpose: Vascular endothelial growth factor (VEGF)-A isa key mediator of angiogenesis in malignant gliomas. Soluble VEGF receptor 1 (sVEGFR-1) can complex VEGF-A and reduce its bioavailability. In several animal models sVEGFR-1 inhibited angiogenesis and tumor growth. We analyzed the levels of endogenous sVEGFR-1 in gliomas of different malignancy grades in relation to tumor vascularity and VEGF-A.

Experimental Design: The concentration of sVEGFR-1 was determined by ELISA in 104 gliomas and normal brain. Levels of sVEGFR-1 were compared with malignancy grade, microvessel density, and VEGF-A concentration. Effects of sVEGFR-1 on glioma extract-induced endothelial cell chemotaxis were analyzed in vitro.

Results: The concentration of sVEGFR-1 correlated with the malignancy grade and was 12-fold higher in glioblastomas than in diffuse astrocytomas (P < 0.001), with intermediate levels for anaplastic astrocytomas. VEGF-A levels were 30-fold higher (P < 0.001) in glioblastomas than in diffuse astrocytomas. The sVEGFR-1:VEGF-A ratio was 0.27 in glioblastomas and 0.70 in diffuse astrocytomas. Both sVEGFR-1 and VEGF-A correlated with microvessel density (P < 0.001) and with each other (P < 0.001); sVEGFR-1 and VEGF-A also correlated with each other when only glioblastomas were analyzed (P = 0.001). In vitro, recombinant sVEGFR-1 inhibited endothelial cell chemotaxis induced by tumor extracts.

Conclusions: Although absolute levels of sVEGFR-1 are increased in the more malignant gliomas, the sVEGFR-1:VEGF-A ratio is decreased 2.6-fold in glioblastomas compared with diffuse astrocytomas, suggesting that the ensuing increased bioavailability of VEGF-A favors angiogenesis. The inhibition of tumor extract-induced endothelial chemotaxis by sVEGFR-1 suggests that sVEGFR-1 could be useful as an angiogenesis inhibitor in the specific context of human gliomas.

This article has been cited by other articles:

				F. T. H. Wu, M. O. Stefanini, F. Mac Gabhann, C. D. Kontos, B. H. Annex, and A. S. Popel Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport Physiol Genomics, June 1, 2009; 38(1): 29 - 41. [Abstract] [Full Text] [PDF]

				P. L. Nghiemphu, W. Liu, Y. Lee, T. Than, C. Graham, A. Lai, R. M. Green, W. B. Pope, L. M. Liau, P. S. Mischel, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience Neurology, April 7, 2009; 72(14): 1217 - 1222. [Abstract] [Full Text] [PDF]

				T. D. Eubank, R. D. Roberts, M. Khan, J. M. Curry, G. J. Nuovo, P. Kuppusamy, and C. B. Marsh Granulocyte Macrophage Colony-Stimulating Factor Inhibits Breast Cancer Growth and Metastasis by Invoking an Anti-Angiogenic Program in Tumor-Educated Macrophages Cancer Res., March 1, 2009; 69(5): 2133 - 2140. [Abstract] [Full Text] [PDF]

				J. M.L. Ebos, C. R. Lee, E. Bogdanovic, J. Alami, P. Van Slyke, G. Francia, P. Xu, A. J. Mutsaers, D. J. Dumont, and R. S. Kerbel Vascular Endothelial Growth Factor Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth Cancer Res., January 15, 2008; 68(2): 521 - 529. [Abstract] [Full Text] [PDF]

				J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, et al. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme J. Clin. Oncol., October 20, 2007; 25(30): 4722 - 4729. [Abstract] [Full Text] [PDF]

				J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. M. Dowell, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clin. Cancer Res., February 15, 2007; 13(4): 1253 - 1259. [Abstract] [Full Text] [PDF]

				C. Chan, J. Sandhu, A. Guha, D. A. Scollard, J. Wang, P. Chen, K. Bai, L. Lee, and R. M. Reilly A Human Transferrin-Vascular Endothelial Growth Factor (hnTf-VEGF) Fusion Protein Containing an Integrated Binding Site for 111In for Imaging Tumor Angiogenesis J. Nucl. Med., October 1, 2005; 46(10): 1745 - 1752. [Abstract] [Full Text] [PDF]

				D. J. Hicklin and L. M. Ellis Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027. [Abstract] [Full Text] [PDF]

				J. M.L. Ebos, G. Bocci, S. Man, P. E. Thorpe, D. J. Hicklin, D. Zhou, X. Jia, and R. S. Kerbel A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma Mol. Cancer Res., June 1, 2004; 2(6): 315 - 326. [Abstract] [Full Text] [PDF]